Effects of corticotropin-releasing hormone on proopiomelanocortin derivatives and monocytic HLA-DR expression in patients with septic shock

Peptides. 2013 Sep:47:133-41. doi: 10.1016/j.peptides.2013.07.013. Epub 2013 Jul 25.

Abstract

Little is known about interactions between immune and neuro-endocrine systems in patients with septic shock. We therefore evaluated whether the corticotropin-releasing hormone (CRH) and/or proopiomelanocortin (POMC) derivatives [ACTH, β-endorphin (β-END), β-lipotropin (β-LPH), α-melanocyte stimulating hormone (α-MSH) or N-acetyl-β-END (Nac-β-END)] have any influences on monocyte deactivation as a major factor of immunosuppression under septic shock conditions. Sixteen patients with septic shock were enrolled in a double-blind, cross-over and placebo controlled clinical study; 0.5μg/(kgbodyweighth) CRH (or placebo) were intravenously administered for 24h. Using flow cytometry we investigated the immunosuppression in patients as far as related to the loss of leukocyte surface antigen-DR expression on circulating monocytes (mHLA-DR). ACTH, β-END immunoreacive material (IRM), β-LPH IRM, α-MSH and Nac-β-END IRM as well as TNF-α and mHLA-DR expression were determined before, during and after treatment with CRH (or placebo). A significant correlation between plasma concentration of α-MSH and mHLA-DR expression and an inverse correlation between mHLA-DR expression and TNF-α plasma level were found. Additionally, a significant increase of mHLA-DR expression was observed 16h after starting the CRH infusion; 8h later, the mHLA-DR expression had decreased again. Our results indicate that the up-regulation of mHLA-DR expression after CRH infusion is not dependent on the release of POMC derivatives. From the correlation between plasma concentration of α-MSH and mHLA-DR expression, we conclude that in patients with septic shock the down-regulation of mHAL-DR expression is accompanied by the loss of monocytic release of α-MSH into the cardiovascular compartment.

Keywords: Alpha melanocyte stimulating hormone (α-MSH); Corticotropin releasing hormone (CRH); Human leukocyte antigen-DR (HLA-DR); Proopiomelanocortin (POMC); Septic shock; Tumor necrosis factor-α (TNF-α).

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adrenocorticotropic Hormone / blood
  • Aged
  • Corticotropin-Releasing Hormone / administration & dosage*
  • Cross-Over Studies
  • Double-Blind Method
  • Female
  • Gene Expression / drug effects
  • HLA-DR Antigens / genetics*
  • HLA-DR Antigens / immunology
  • Hospitals, University
  • Humans
  • Infusions, Intravenous
  • Intensive Care Units
  • Male
  • Middle Aged
  • Monocytes / drug effects
  • Monocytes / immunology
  • Monocytes / metabolism*
  • Monocytes / pathology
  • Prospective Studies
  • Shock, Septic / drug therapy
  • Shock, Septic / immunology
  • Shock, Septic / metabolism*
  • Shock, Septic / pathology
  • alpha-MSH / blood
  • beta-Endorphin / analogs & derivatives
  • beta-Endorphin / blood
  • beta-Lipotropin / blood

Substances

  • HLA-DR Antigens
  • alpha-MSH
  • beta-Endorphin
  • N-acetyl-beta-endorphin
  • Adrenocorticotropic Hormone
  • Corticotropin-Releasing Hormone
  • beta-Lipotropin